Genentech Oncology
TIGIT is a coinhibitory receptor that binds to PVR on APCs and tumor cells in various solid and hematologic tumors.1-3 TIGIT dampens the immune response by competing with its costimulatory counterpart, CD226, for binding to PVR.1,2 Preventing PVR-TIGIT interaction may restore anti-tumor immunity, thereby complementing PD-L1 inhibition, as shown in preclinical models.1 TIGIT was identified at Genentech.2,4
Targeting TIGIT may enhance Teff function.1
Targeting TIGIT may activate NK cells.5
Targeting TIGIT may counter T reg-mediated immune suppression.6
APC=antigen-presenting cell; IgG1=immunoglobulin G1; NK=natural killer; PD-1=programmed cell death protein 1; PD-L1=programmed cell-death ligand 1; PVR=poliovirus receptor; Teff=effector T cell; Treg=regulatory T cell; TIGIT=T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains.
Johnston RJ, Comps-Agrar L, Hackney J, et al. Cancer Cell. 2014;26(6):923-937. PMID: 25465800
Johnston RJ, Comps-Agrar L, Hackney J, et al. Cancer Cell. 2014;26(6):923-937. PMID: 25465800
Yu X, Harden K, Gonzalez LC, et al. Nat Immunol. 2009;10(1):48-57. PMID: 19011627
Yu X, Harden K, Gonzalez LC, et al. Nat Immunol. 2009;10(1):48-57. PMID: 19011627
Sanchez-Correa B, Valhondo I, Hassouneh F, et al. Cancers (Basel). 2019;11(6):877. PMID: 31234588
Sanchez-Correa B, Valhondo I, Hassouneh F, et al. Cancers (Basel). 2019;11(6):877. PMID: 31234588
Abbas AR, Baldwin D, Ma Y, Ouyang W, et al. Genes Immun. 2005;6(4):319-331. PMID: 15789058
Abbas AR, Baldwin D, Ma Y, Ouyang W, et al. Genes Immun. 2005;6(4):319-331. PMID: 15789058
Stanietsky N, Simic H, Arapovic J, et al. Proc Natl Acad Sci USA. 2009;106(42):17858-17863. PMID: 19815499
Stanietsky N, Simic H, Arapovic J, et al. Proc Natl Acad Sci USA. 2009;106(42):17858-17863. PMID: 19815499
Kurtulus S, Sakuishi K, Ngiow SF, et al. J Clin Invest. 2015;125(11):4053-4062. PMID: 26413872
Kurtulus S, Sakuishi K, Ngiow SF, et al. J Clin Invest. 2015;125(11):4053-4062. PMID: 26413872
Discover our broad range of antitumor modalities.
Learn more about the importance of cancer biomarkers.
The compounds and their uses mentioned on this website are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. Do you wish to proceed?
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.